BeiGene Says It Will Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax In High-Risk First-Line CLL/SLL At EHA2024, Preliminary Data Suggests Efficacy And Tolerability

6/14/24 6:04:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BGNE alert in real time by email

BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session. The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) with del(17p) and/or TP53 mutation. The preliminary data demonstrate that in the 65 response-evaluable patients treated with the combination, the overall response rate (ORR) was 100%, and the rate of complete response (CR) plus CR with incomplete hematopoietic recovery (CRi) was 48%. The safety profile of the combination is consistent with that of the treatment components, and no new safety signals were seen.

Get the next $BGNE alert in real time by email

Date	Price Target	Rating	Analyst
9/18/2024	$288.00	Mkt Outperform	JMP Securities
2/6/2024	$185.00	Overweight	JP Morgan
9/12/2023	$259.00	Outperform	Macquarie
8/17/2023	$287.00	Buy	Jefferies
7/17/2023	$275.00	Buy	Citigroup
6/30/2023	$335.00 → $196.00	Outperform → Mkt Perform	Bernstein
1/12/2023	$308.00	Buy	Daiwa Securities
10/13/2022	$205.00	Neutral → Buy	Guggenheim

BeiGene Says It Will Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax In High-Risk First-Line CLL/SLL At EHA2024, Preliminary Data Suggests Efficacy And Tolerability

Chat with this insight

Recent Analyst Ratings for $BGNE

$BGNE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on BeiGene with a new price target

JP Morgan resumed coverage on BeiGene with a new price target

Macquarie initiated coverage on BeiGene with a new price target

$BGNE Leadership Updates

Live Leadership Updates

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

BeiGene Announces Updates to Commercial Leadership Team

$BGNE Market Insights

Live Market Insights

BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment

Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition

BeiGene shares are trading lower after B of A Securities maintained a Neutral rating on the stock and lowered its price target from $180 to $152.5

$BGNE Press Releases

Fastest customizable press release news feed in the world

$BGNE SEC Filings

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13D/A filed by BeiGene Ltd.

$BGNE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

SEC Form SC 13G/A filed by BeiGene Ltd. (Amendment)

SEC Form SC 13G/A filed by BeiGene Ltd. (Amendment)

$BGNE Financials

Live finance-specific insights

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

$BGNE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Oyler John sold $3,756,092 worth of American Depositary Shares (16,175 units at $232.22), closing all direct ownership in the company (SEC Form 4)

Director Sharp Shalini was granted 8,151 units of Ordinary Shares (SEC Form 4)

SEC Form 3 filed by new insider Sharp Shalini

Recent Analyst Ratings for
$BGNE

$BGNE
Analyst Ratings

$BGNE
Leadership Updates

$BGNE
Market Insights

$BGNE
Press Releases

$BGNE
SEC Filings

$BGNE
Large Ownership Changes

$BGNE
Financials

$BGNE
Insider Trading